A study reveals that combining efruxifermin (EFX) with a GLP-1 receptor agonist (GLP-1RA) is a safe and tolerable dual therapy for MASH and type 2 diabetes patients.
The non-alcoholic steatohepatitis (NASH) market is poised for substantial growth, projected to expand significantly by 2032 across the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Boston Pharmaceuticals' efimosfermin alfa demonstrated statistically significant fibrosis improvement in MASH patients, with 45.2% showing at least a one-stage improvement compared to 20.6% in the placebo group.
Akero Therapeutics' efruxifermin (EFX) demonstrates significant anti-fibrotic effects in patients with F2/F3 MASH, as shown in the Phase 2b HARMONY study.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.